13/02/2016 18:45:22 1-888-992-3836 (toll free) Free Membership Login

Mylan N.V. News (NASDAQ:MYL)

DateTimeSource
Headline
02/11/20169:42AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to trade actively in Thursday's session are TripAdvisor Inc. (TRIP), Teva Pharmaceuticals Industries Ltd. (TEVA) and PepsiCo Inc. (PEP). TripAdvisor Inc. on Thursday reported a core profit that beat Wall Street expectations for the first time since 2013, as higher display advertising... More...>>
02/11/20168:50AMDJNTeva Pharmaceuticals Reports Sales Decline
Teva Pharmaceuticals Industries Ltd. reported a decline in revenue as drug sales fell across its generic and specialty segments. The company also released projections for the current quarter, saying it expects adjusted earnings in the range of $1.16 to $1.20 and revenue of $4.7 billion to $4.9 billion. When the impacts... More...>>
02/10/20165:10PMDJNMylan Reaches $7.2 Billion Deal For Sweden's Meda
Mylan NV said Wednesday that it has agreed to buy Swedish pharmaceutical company Meda AB for $7.2 billion in cash and stock, while the drug maker also reported slower-than-expected growth in its fourth quarter. Shares of Mylan fell 7.4% to $46.80 a share in after-hours trading. Mylan had attempted to buy Meda back in 2014... More...>>
02/10/20164:10PMPRNUSMylan Full Year Adjusted Diluted EPS Up 21% to $4.30
Mylan Full Year Adjusted Diluted EPS Up 21% to $4.30 Provides 2016 Adjusted Diluted EPS Guidance Range of $4.85 to $5.15, With or Without Meda, Representing Year-Over-Year Growth of 16% Anticipates 2016 Total Revenues of $10.5 billion to $11.5 billion, With or Without Meda, Representing Year-Over-Year Growth of 16% PR... More...>>
02/10/20164:01PMPRNUSMylan to Acquire Meda
Mylan to Acquire Meda PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Feb. 10, 2016 HERTFORDSHIRE, England and PITTSBURGH, Feb. 10, 2016 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on... More...>>
02/10/20164:01PMPRNUSMylan to Acquire Meda
Mylan to Acquire Meda PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Feb. 10, 2016 HERTFORDSHIRE, England and PITTSBURGH, Feb. 10, 2016 /PRNewswire/ --  The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or... More...>>
01/21/20162:57PMPRNUSMylan to Report Fourth Quarter and Full Year 2015 Financial Results on Feb. 10, 2016
Mylan to Report Fourth Quarter and Full Year 2015 Financial Results on Feb. 10, 2016 PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Jan. 21, 2016 HERTFORDSHIRE, England and PITTSBURGH, Jan. 21, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast... More...>>
01/19/201610:26AMPRNUSMylan Launches Generic Felbatol® Tablets
Mylan Launches Generic Felbatol® Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Jan. 19, 2016 HERTFORDSHIRE, England and PITTSBURGH, Jan. 19, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Felbamate Tablets USP, 400 mg and 600 mg, which is the generic version of Meda... More...>>
01/11/20165:11PMPRNUSMylan Confirms FDA Submission of ANDA for Generic Advair Diskus®
Mylan Confirms FDA Submission of ANDA for Generic Advair Diskus® PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Jan. 11, 2016 HERTFORDSHIRE, England and PITTSBURGH, Jan. 11, 2016 /PRNewswire/ -- In advance of its upcoming presentation at the J.P. Morgan Annual Healthcare Conference tomorrow, Mylan N.V. (NASDAQ, TASE:... More...>>
01/08/20169:50AMDJNMomenta, Mylan to Jointly Develop Six Biosimilars
Mylan NV and Momenta Pharmaceuticals Inc. said Friday they would jointly develop and commercialize six biosimilars. Mylan will make an upfront cash payment of $45 million to Momenta and could pay up to $200 million if milestones are reached. Each company will equally share the development costs and eventual profits. Mylan... More...>>
01/08/20169:00AMPRNUSMylan CFO John Sheehan to Retire as of April 1, 2016
Mylan CFO John Sheehan to Retire as of April 1, 2016 PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Jan. 8, 2016 HERTFORDSHIRE, England and PITTSBURGH, Jan. 8, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that John Sheehan has advised the company of his intention to retire from his position... More...>>
01/08/20168:00AMPRNUSMylan Announces Worldwide Collaboration with Momenta to Jointly Develop and Commercialize Six Biosimilar Products
Mylan Announces Worldwide Collaboration with Momenta to Jointly Develop and Commercialize Six Biosimilar Products Partnership Builds on Successful Existing Collaboration with Biocon and Positions Mylan as a World Leader in Biosimilars PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Jan. 8, 2016 HERTFORDSHIRE, England... More...>>
01/08/20168:00AMGLOBEMomenta Pharmaceuticals Announces Worldwide Collaboration With Mylan to Jointly Develop and Commercialize Six Biosimilar Prod...
CAMBRIDGE, Mass., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that it has entered into an exclusive global collaboration agreement with Mylan N.V. (Nasdaq:MYL), (TASE:MYL) to develop, manufacture and commercialize six of Momenta’s current biosimilar candidates, including... More...>>
01/08/20168:00AMGLOBEMomenta Pharmaceuticals Announces Worldwide Collaboration With Mylan to Jointly Develop and Commercialize Six Biosimilar Prod...
CAMBRIDGE, Mass., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that it has entered into an exclusive global collaboration agreement with Mylan N.V. (Nasdaq:MYL), (TASE:MYL) to develop, manufacture and commercialize six of Momenta’s current biosimilar candidates, including... More...>>
01/07/20168:00AMPRNUSMylan Launches Generic Harvoni® (Ledipasvir/Sofosbuvir) Under the Brand Name MyHep LVIR™ in India
Mylan Launches Generic Harvoni® (Ledipasvir/Sofosbuvir) Under the Brand Name MyHep LVIR™ in India PR Newswire HERTFORDSHIRE, England and BANGALORE, India and PITTSBURGH, Jan. 7, 2016 HERTFORDSHIRE, England and BANGALORE, India and PITTSBURGH, Jan. 7, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced... More...>>
01/05/201610:34AMPRNUSMylan Launches Generic Ortho Tri-Cyclen Lo® Tablets
Mylan Launches Generic Ortho Tri-Cyclen Lo® Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Jan. 5, 2016 HERTFORDSHIRE, England and PITTSBURGH, Jan. 5, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Norgestimate and Ethinyl Estradiol Tablets USP, 0.18 mg/0.025 mg, 0.215... More...>>
01/02/20163:02AMDJNBests And Bloopers From M&A's Epic Year
(FROM THE WALL STREET JOURNAL 1/2/16) A high-stakes affair in normal times, corporate deal making took on even greater weight in 2015, the busiest year ever for mergers. At the end of the roughly $5 trillion year, The Wall Street Journal's deals team presents its view on who gained the most from the bonanza, and who... More...>>
12/29/20157:00AMPRNUSMylan Launches Generic Zyvox® Tablets
Mylan Launches Generic Zyvox® Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2015 HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Linezolid Tablets, 600 mg, which is the generic version of Pfizer's Zyvox® Tablets... More...>>
12/17/20157:15AMPRNUSMylan to Present at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
Mylan to Present at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 17, 2015 HERTFORDSHIRE, England and PITTSBURGH, Dec. 17, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that CEO Heather Bresch will present at the Goldman... More...>>
12/17/20157:00AMPRNUSMylan to Present at the J.P. Morgan 34th Annual Healthcare Conference
Mylan to Present at the J.P. Morgan 34th Annual Healthcare Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 17, 2015 HERTFORDSHIRE, England and PITTSBURGH, Dec. 17, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the Company will present at the J.P. Morgan 34th Annual Healthcare... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20160213 23:45:23